fda update on semaglutide Approves Oral Semaglutide: First GLP-1 Weight Loss Pill FDA Warns on Certain Forms

***Although these products are safe, they are contraindicated for the following patients: Thyroid cancer, gallbladder disease, pancreatitis, Endocrine disorders, pregnancy

Nasal Irritation: Temporary dryness, itching, or congestion in the nasal passages

Understanding Semaglutides function and benefits is essential for exploring its safety during pregnancy, as it involves managing critical hormones and bodily functions that could impact both maternal and fetal health

Hughes JL, Horowitz LM, Ackerman JP, Adrian MC, Campo JV, Bridge JA

Wegovy is the first once-weekly GLP-1 receptor agonist approved as a weight loss medication for people under the age of 18

Injectable is superior for systemic effects, internal tissue repair, and when maximum bioavailability is needed